The American College of Cardiology (ACC), the American Heart Association (AHA), and nine other medical organizations have issued updated guidelines for managing dyslipidemia, replacing the 2018 AHA/ACC cholesterol guidance. The revision reflects growing evidence that atherogenic lipoproteins beyond low-density lipoprotein cholesterol (LDL-C) — including triglyceride-rich remnant particles and lipoprotein(a) [Lp(a)] — contribute to atherosclerotic cardiovascular disease (ASCVD).
The guideline-writing committee notes that much cardiovascular disease is preventable and that elevated LDL is a major modifiable risk factor. While lifestyle optimization remains the first-line approach, the new guidance encourages earlier consideration of lipid-lowering medications when lipid levels remain above desired ranges after lifestyle measures. The rationale is that lowering LDL earlier and maintaining lower levels for longer reduces lifetime exposure to harmful lipids and thus lowers heart attack and stroke risk.
Scope and emphasis
– The guidelines consolidate evidence-based recommendations into a single document covering assessment and treatment of multiple blood lipids to reduce ASCVD risk.
– There is renewed emphasis on early detection of hyperlipidemia, clearer LDL-C targets, and individualized treatment based on lifetime risk.
– Reintroducing LDL targets is intended to make treatment decisions more actionable for clinicians and patients.
Risk assessment: PREVENT-ASCVD equations
– The guidelines recommend the AHA PREVENT-ASCVD equations for primary prevention risk estimation. These contemporary calculators estimate 10- and 30-year risk of heart attack and stroke for adults aged 30–79 without known ASCVD or subclinical atherosclerosis and with specified LDL levels.
– PREVENT-ASCVD uses routine clinical data (cholesterol, blood pressure, age, habits) and allows incorporation of “risk enhancers” to personalize risk estimates and guide decisions about initiating lipid-lowering therapy.
Selective additional testing
To improve risk stratification and decide on more intensive LDL lowering, the guidelines recommend considering additional tests when appropriate:
– Coronary artery calcium (CAC) scan (non-contrast): Selective use can detect early calcified plaque and help inform statin decisions by revealing subclinical atherosclerosis.
– Lipoprotein(a) [Lp(a)]: Measure at least once in adulthood because levels are largely genetic and stable over a lifetime; elevated Lp(a) is an independent ASCVD risk factor.
– Apolipoprotein B (apoB): Useful for assessing residual ASCVD risk and guiding therapy among people with cardiometabolic conditions, type 2 diabetes, high triglycerides, or established cardiovascular disease who have reached LDL-C and non–HDL-C goals.
Treatment approach
– Lifestyle interventions remain foundational: heart-healthy diet, physical activity, weight management, smoking cessation, and blood pressure control.
– If LDL-C remains above target after lifestyle optimization, clinicians should consider earlier initiation of statin therapy than in past practice, aiming for lower LDL levels for longer durations.
– For patients whose LDL-C is not adequately controlled with lifestyle measures and statins, the guidelines support adding non-statin therapies to achieve LDL goals.
– The updated recommendations promote a move away from one-size-fits-all care toward integrating clinical factors, imaging, and biomarkers to personalize prevention strategies.
Overall message
The new guidelines reflect a shift toward earlier intervention, better risk stratification, and personalized but structured prevention of cardiovascular disease. By identifying risk sooner and aiming for sustained lower LDL-C, clinicians can more effectively reduce lifetime ASCVD risk.
